Company intelligence / Profile preview
bene-Arzneimittel GmbH
Munich/München, Bavaria/Bayern, Germanybene-arzneimittel.de ↗
- Ownership
- Private
- Employees
- ~120
- Development stage
- Other
01
Overview
Bene-Arzneimittel has a long history of developing and commercializing pharmaceuticals focused on analgesia, pediatrics, urology, and inflammation. Its flagship products include ben-u-ron® (paracetamol) widely used for pain/fever since the late 1950s; elmiron®, the first EU-approved drug therapy for bladder pain syndrome/interstitial cystitis; as well as proprietary sodium pentosan polysulfate preparations.
- Therapeutic areas
- OtherCardiovascularNephrology
- Modalities
- Small molecules (notably sodium pentosan polysulfate/NaPPS, paracetamol, ibuprofen)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborates with established partners globally to distribute products in over 30 countries
Beyond the preview
Go deeper on bene-Arzneimittel GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bene-Arzneimittel GmbH.